EU Clears Kohlberg, Montagu, Teleflex OEM Merger
Summary
The European Commission cleared the acquisition of joint control over the Teleflex OEM Business by US private equity firms Kohlberg & Company and Montagu Private Equity under case M.12301. The Commission determined the transaction, which involves medical device component manufacturing, does not raise competition concerns in the internal market. The decision was adopted under Article 6(1)(b) of the EC Merger Regulation using the simplified treatment procedure.
“For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement.”
What changed
The European Commission issued a clearance decision for the proposed acquisition of joint control over the Teleflex OEM Business by Kohlberg & Company and Montagu Private Equity. The transaction was reviewed under the simplified treatment procedure for certain concentrations under the EC Merger Regulation. The Commission concluded that the notified operation falls within the scope of Regulation (EC) No 139/2004 and declared it compatible with the internal market and the EEA Agreement.\n\nAffected parties in transactions involving private equity acquisitions of healthcare and medical device businesses that meet EU merger notification thresholds should ensure timely filing with the Commission and assess whether simplified treatment criteria apply. Parties operating in the medical device manufacturing sector should monitor competition effects from private equity consolidation in their supply chain.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Case M.12301 - KOHLBERG /
MONTAGU / TELEFLEX OEM BUSINESS
Only the English text is available and authentic. REGULATION (EC) No 139/2004
MERGER PROCEDURE
Article 6(1)(b)
Date: 20/04/2026
In electronic form on the EUR-Lex website under document number 32026M12301
EUROPEAN COMMISSION
DG Competition
Brussels, 20.4.2026 C(2026) 2693 final
PUBLIC VERSION
Kohlberg & Company, L.L.C 111 Radio Circle Mount Kisco, NY 10549 United States Montagu Private Equity LLP 2 More London Riverside London, SE1 2AP United Kingdom
Subject: Case M.12301 - KOHLBERG / MONTAGU / TELEFLEX OEM BUSINESS Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 ( ) and Article 57 of the Agreement on the European 1 Economic Area ( ) 2
Dear Sir or Madam, (1) On 23 March 2026, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation, by which Kohlberg & Company, L.L.C, ('Kohlberg', United States), and Montagu Private Equity
LLP ('Montagu', United Kingdom), will acquire within the meaning of Article
3(1)(b) of the Merger Regulation joint control over the whole of the Teleflex OEM Business, (United States) by way of purchase of shares. ( ) 3 (2) The business activities of the undertakings concerned are the following:
- Kohlberg is a US private equity firm. Kohlberg invests in various
companies operating across the world, with a focus on the US. Kohlberg specialises in investments in healthcare and services companies,
() OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty 1
on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The
terminology of the TFEU will be used throughout this decision. () OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement'). 2 () OJ C, C/2026/1978, 31.3.2026. 3
EUROPEAN COMMISSION
- Montagu, a limited liability partnership established under English law, is a
private equity investor investing in a variety of sectors, including healthcare. (3) The Teleflex OEM Business designs, develops, and manufactures components and finished devices for other medical device companies. Its services include creating custom-engineered diagnostic and interventional components and devices. Teleflex OEM Business is active in North America, Australia Pacific, EMEA, and Latin America. (4) After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraphs 5 (b) and 5 (d) of the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004. ( ) 4 (5) For the reasons set out in the Notice on a simplified treatment, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.
For the Commission
(Signed)
Anthony WHELAN
Director-General Directorate-General for Competition
() OJ C 160, 5.5.2023, p. 1 (the 'Notice on a simplified treatment'). 4
Named provisions
Mentioned entities
Related changes
Get daily alerts for EC Competition Cases
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EC.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EC Competition Cases publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.